ONCAlert | 2018 ASCO Annual Meeting
Multiple Myeloma Case Studies

Case Studies: Monoclonal Antibodies in Relapsed Multiple Myeloma with Ola Landgren, MD, PhD

Ola Landgren, MD, PhD, reviews the goals of therapy and treatment options with monoclonal antibodies in relapsed multiple myeloma using case-based scenarios.

Monoclonal Antibodies in Relapsed Multiple Myeloma with Ola Landgren, MD, PhD: Case 2

Case Scenario 2:

January 2015

  • The patient is a 72-year old female who was diagnosed with ISS stage I multiple myeloma.
  • She is an insulin dependent diabetic who is experiencing peripheral neuropathy.
  • Her cytogenetics were classified as standard risk, bone marrow show 50% light chain restricted plasma cells.
  • M-spike IgG lambda 2.5 g/dL,
  • Performance status 1.
  • She received treatment with lenalidomide (25 mg daily) and low-dose dexamethasone and obtains a very good partial response.
  • After a year she decided to come off of lenalidomide therapy.

       July 2016

  • Six months after stopping therapy,patient had increasing fatigue and weakness.
  • M-spike is now 0.8 g/dL.
  • CT scan revealed several bone lesions.
  • Patient was started on daratumumab, lenalidomide and dexamethasone

 

Publications
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.